🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity · Phase II

Metabolic & obesity programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
210

Quick answer

Metabolic & obesity Phase II programs: NovaPharmaNews indexes 210 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 4 of 5

  1. Placebo to match LY3556050

    Eli Lilly Co.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  2. Pramlintide+Metreleptin

    Takeda

    Obesity

    phase 2 small molecule terminated

    1 trial

  3. Pro insulin peptide

    Cardiff Oncology

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  4. REGN910-3

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  5. RO7204239, RO7204239 Placebo, Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-f

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

  6. Rencofilstat

    Hepion Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  7. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    MASH - Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  8. Rybelsus 9 mg tablets, Rybelsus 1.5 mg tablets, Rybelsus 4 mg tablets, RO7795081, Rybelsus 7 mg tablets, RO7795081, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets, RO7795081, oral GLP-1R agonist (CT-996) Capsule, hard 0 mg / 1 EA - F10

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2D)

    phase 2 small molecule active

    1 trial

  9. SAB-142, SODIUM CHLORIDE

    SAB Biotherapeutics

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  10. SB-509

    SANGAMO THERAPEUTICS, INC

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    4 trials

  11. SHR20004

    Jian Li

    Obesity

    phase 2 small molecule active

    1 trial

  12. SYR-619

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  13. Saxenda 6 mg/mL solution for injection in pre-filled pen, Saxenda 6 mg/mL solution for injection in pre-filled pen, Placebo for PF-07976016, Saxenda 6 mg/mL solution for injection in pre-filled pen

    Pfizer Australia Pty Ltd

    Obesity, Overweight

    phase 2 small molecule active

    1 trial

  14. Selinexor

    Karyopharm Therapeutics Inc

    Diabetic Foot Ulcers

    phase 2 small molecule terminated

    1 trial

  15. Semaglutide (Rybelsus®)

    The First People's Hospital of Lianyungang

    Obesity-related Male Infertility

    phase 2 small molecule active

    1 trial

  16. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Genetic Obesity

    phase 2 small molecule completed

    2 trials

  17. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Overweight and Obesity

    phase 2 small molecule completed

    1 trial

  18. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes

    phase 2 small molecule active

    2 trials

  19. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    chronic limb-threatening ischemia, diabetic foot ulcers

    phase 2 small molecule active

    1 trial

  20. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  21. TAK-128

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule terminated

    2 trials

  22. TAK-272

    Takeda

    Type 2 Diabetes Mellitus and Microalbuminuria

    phase 2 small molecule completed

    1 trial

  23. TAK-379

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  24. TAK-583

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  25. TAK-906 Maleate

    Takeda

    Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

    phase 2 small molecule completed

    1 trial

  26. TAK-906 Maleate

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  27. TAK-954

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  28. TG-873870 (Nemonoxacin)

    Biotech Pharmaceutical Co.,

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  29. TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, IOHEXOL , TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  30. TTP054

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  31. TTP273

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  32. TTP399

    vTv Therapeutics

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    1 trial

  33. TTP399 400 mg

    vTv Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  34. TTP435

    vTv Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  35. TVB-2640

    Sagimet Biosciences

    Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  36. TVB-2640 25 mg (US)

    Sagimet Biosciences

    MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

    phase 2 small molecule completed

    1 trial

  37. Tangweian Recipe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diabetic Gastroenteropathy

    phase 2 small molecule active

    1 trial

  38. Thiogamma 600 mg Filmtabletten, Benfogamma Forte, 300 mg, tabletki powlekane

    Lacuna Pharma Pty Ltd

    Diabetic sensorimotor polyneuropathy (DSPN)

    phase 2 small molecule active

    1 trial

  39. Tirzepatide

    Regeneron UK Limited

    Obesity

    phase 2 small molecule completed

    1 trial

  40. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Nisotirotide, placebo to match LY, Tirzepatide

    Eli Lilly Co.

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  41. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Obesity

    phase 2 small molecule completed

    1 trial

  42. Trevogrumab-Part A

    Regeneron UK Limited

    Obesity

    phase 2 small molecule active

    1 trial

  43. UBT251

    United Therapeutics Europe Ltd

    Metabolic Dysfunction-associated Steatohepatitis (MASH)

    phase 2 small molecule active

    1 trial

  44. UBT251

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule active

    1 trial

  45. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule completed

    1 trial

  46. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule completed

    1 trial

  47. VC-02 Combination Product

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus With Hypoglycemia

    phase 2 other completed

    1 trial

  48. VK2809

    Viking Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many metabolic & obesity Phase II programs exist?

210 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.